Michael Howell, Ph.D.
Chief Scientific Officer
Michael Howell, Ph.D., is an immunologist with more than 20 years of experience in the government, academia, and the biopharma/biotech sectors. Prior to joining DermTech, Dr. Howell was a faculty member at National Jewish Health and held increasing positions of responsibility at Boehringer Ingelheim, MedImmune/AstraZeneca, and Incyte Corporation. Dr. Howell has previously led research and development teams dedicated to the discovery of novel therapies for dermatology and the integration of novel biomarker approaches including adhesive tape strips into clinical development. His efforts have led to the approval of multiple therapies, novel diagnostic approaches to patient treatment, and have been highlighted in more than 50 publications and numerous patents. Dr. Howell received his Ph.D. in Immunology from West Virginia University and completed his post-doctoral training at National Jewish Health.